

**Prior Authorization**

Certain drugs require prior authorization to help promote safe, quality and affordable pharmacy care. Your doctor will need to submit a prior authorization request to Prime Therapeutics, which must be approved before you can continue to receive coverage for these drugs.

The Prior Authorization form that your physician will need to complete to request an approval can be found on the MyPrime website.

**Quantity Limit Consideration**

Within the Prior Authorization program, Quantity Limit may apply. If there is medical reason why you need an amount that is greater than what is allowed, your physician can fill out a Quantity Limit prior authorization form for you and send it to Prime Therapeutics. This form can be found on the MyPrime.com website.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
<b>Acute Migraine Agents</b>		dihydroergotamine mesylate
		ELYXYB
		MIGRANAL
		REYVOW
		TRUDHESA
<b>Afrezza</b>		AFREZZA
<b>Agamree Emflaza</b>		AGAMREE
		deflazacort
		EMFLAZA
<b>Amifampridine</b>		FIRDAPSE
<b>Androgen/Anabolic Steroids</b>		ANDROGEL PUMP
		danazol
		FORTESTA
		JATENZO
		KYZATREX
		METHITEST
		methyltestosterone

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner®. NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		NATESTO
		TESTIM
		TESTOSTERONE
		TESTOSTERONE PUMP
		testosterone topical solution
		TLANDO
		UNDECATREX
		VOGELXO
		VOGELXO PUMP
<b>Arikayce</b>		ARIKAYCE
<b>ATTR Amyloidosis</b>		ATTRUBY
		TEGSEDI
		VYNDAMAX
		VYNDAQEL
		WAINUA
<b>Bempedoic Acid</b>		NEXLETOL
		NEXLIZET
<b>Biologic Immunomodulators</b>	<b>Preferred Products: Refer to Policy</b>	ABRILADA
	<b>Preferred Products: Refer to Policy</b>	ABRILADA 1-PEN KIT
	<b>Preferred Products: Refer to Policy</b>	ABRILADA 2-PEN KIT
	<b>Preferred Products: Refer to Policy</b>	ACTEMRA
	<b>Preferred Products: Refer to Policy</b>	ACTEMRA ACTPEN
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AACF (2 PEN)
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AACF (2 SYRINGE)
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AACF STARTER PACK/CD/UC/HS (6 PEN)
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AACF STARTER PACK/PSORIASIS/UEVITIS (4 PEN)
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AATY 1-PEN KIT
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AATY 2-PEN KIT
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AATY 2-SYRINGE KIT
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-AATY CD/UC/HS STARTER
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-ADAZ
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-ADBM
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-ADBM CROHNS/UC/HS STARTER
	<b>Preferred Products: Refer to Policy</b>	ADALIMUMAB-ADBM PSORIASIS/UEVITIS STARTER

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Refer to Policy	ADALIMUMAB-ADB M STARTER PACKAGE FOR CROHNS DISEASE/UC/HS
	Preferred Products: Refer to Policy	ADALIMUMAB-ADB M STARTER PACKAGE FOR PSORIASIS/UVEITIS
	Preferred Products: Refer to Policy	ADALIMUMAB-FKJP
	Preferred Products: Refer to Policy	ADALIMUMAB-RYVK
	Preferred Products: Refer to Policy	ADALIMUMAB-RYVK (2 PEN)
	Preferred Products: Refer to Policy	AMJEVITA
	Preferred Products: Refer to Policy	BIMZELX
	Preferred Products: Refer to Policy	CIMZIA
	Preferred Products: Refer to Policy	CIMZIA STARTER KIT
	Preferred Products: Refer to Policy	COSENTYX
	Preferred Products: Refer to Policy	COSENTYX SENSOREADY PEN
	Preferred Products: Refer to Policy	COSENTYX UNOREADY
	Preferred Products: Refer to Policy	CYLTEZO
	Preferred Products: Refer to Policy	CYLTEZO STARTER PACKAGE FOR CROHNS DISEASE/UC/HS
	Preferred Products: Refer to Policy	CYLTEZO STARTER PACKAGE FOR PSORIASIS
	Preferred Products: Refer to Policy	CYLTEZO STARTER PACKAGE FOR PSORIASIS/UVEITIS
	Preferred Products: Refer to Policy	ENBREL
	Preferred Products: Refer to Policy	ENBREL MINI
	Preferred Products: Refer to Policy	ENBREL SURECLICK
	Preferred Products: Refer to Policy	ENTYVIO PEN
	Preferred Products: Refer to Policy	HADLIMA
	Preferred Products: Refer to Policy	HADLIMA PUSH TOUCH
	Preferred Products: Refer to Policy	HULIO
	Preferred Products: Refer to Policy	HUMIRA
	Preferred Products: Refer to Policy	HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK
	Preferred Products: Refer to Policy	HUMIRA PEN
	Preferred Products: Refer to Policy	HUMIRA PEN-CD/UC/HS STARTER
	Preferred Products: Refer to Policy	HUMIRA PEN-PEDIATRIC UC STARTER PACK
	Preferred Products: Refer to Policy	HUMIRA PEN-PS/UV STARTER
	Preferred Products: Refer to Policy	HYRIMOZ
	Preferred Products: Refer to Policy	HYRIMOZ CROHN'S DISEASE AND ULCERATIVE COLITIS STARTER PACK
	Preferred Products: Refer to Policy	HYRIMOZ PEDIATRIC CROHNS DISEASE STARTER PACK

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Refer to Policy	HYRIMOZ PEDIATRIC CROHN'SDISEASE STARTER PACK
	Preferred Products: Refer to Policy	HYRIMOZ PLAQUE PSORIASIS STARTER PACK
	Preferred Products: Refer to Policy	HYRIMOZ PLAQUE PSORIASIS/UEITIS STARTER PACK
	Preferred Products: Refer to Policy	HYRIMOZ SENSOREADY PENS
	Preferred Products: Refer to Policy	IDACIO (2 PEN)
	Preferred Products: Refer to Policy	IDACIO (2 SYRINGE)
	Preferred Products: Refer to Policy	IDACIO STARTER PACKAGE FOR CROHNS DISEASE
	Preferred Products: Refer to Policy	IDACIO STARTER PACKAGE FOR PLAQUE PSORIASIS
	Preferred Products: Refer to Policy	IMULDOSA
	Preferred Products: Refer to Policy	KEVZARA
	Preferred Products: Refer to Policy	KINERET
	Preferred Products: Refer to Policy	LEQSELVI
	Preferred Products: Refer to Policy	LITFULO
	Preferred Products: Refer to Policy	OLUMIANT
	Preferred Products: Refer to Policy	OMVOH
	Preferred Products: Refer to Policy	ORENCIA
	Preferred Products: Refer to Policy	ORENCIA CLICKJECT
	Preferred Products: Refer to Policy	OTULFI
	Preferred Products: Refer to Policy	PYZCHIVA
	Preferred Products: Refer to Policy	RINVOQ
	Preferred Products: Refer to Policy	RINVOQ LQ
	Preferred Products: Refer to Policy	SELARSDI
	Preferred Products: Refer to Policy	SILIQ
	Preferred Products: Refer to Policy	SIMLANDI
	Preferred Products: Refer to Policy	SIMLANDI 1-PEN KIT
	Preferred Products: Refer to Policy	SIMLANDI 2-PEN KIT
	Preferred Products: Refer to Policy	SIMPONI
	Preferred Products: Refer to Policy	SKYRIZI
	Preferred Products: Refer to Policy	SKYRIZI PEN
	Preferred Products: Refer to Policy	SOTYKTU
	Preferred Products: Refer to Policy	STELARA
	Preferred Products: Refer to Policy	STEQEYMA
	Preferred Products: Refer to Policy	TALTZ
	Preferred Products: Refer to Policy	TREMFYA
	Preferred Products: Refer to Policy	TREMFYA INDUCTION PACK FOR CROHNS DISEASE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Refer to Policy	TREMFYA PEN
	Preferred Products: Refer to Policy	TYENNE
	Preferred Products: Refer to Policy	USTEKINUMAB
	Preferred Products: Refer to Policy	USTEKINUMAB-AEKN
	Preferred Products: Refer to Policy	USTEKINUMAB-TTWE
	Preferred Products: Refer to Policy	VELSIPITY
	Preferred Products: Refer to Policy	WEZLANA
	Preferred Products: Refer to Policy	XELJANZ
	Preferred Products: Refer to Policy	XELJANZ XR
	Preferred Products: Refer to Policy	YESINTEK
	Preferred Products: Refer to Policy	YUFLYMA 1-PEN KIT
	Preferred Products: Refer to Policy	YUFLYMA 2-PEN KIT
	Preferred Products: Refer to Policy	YUFLYMA 2-SYRINGE KIT
	Preferred Products: Refer to Policy	YUFLYMA CD/UC/HS STARTER
	Preferred Products: Refer to Policy	YUSIMRY
	Preferred Products: Refer to Policy	ZYMFENTRA 1-PEN
	Preferred Products: Refer to Policy	ZYMFENTRA 2-PEN
	Preferred Products: Refer to Policy	ZYMFENTRA 2-SYRINGE
<b>Bonjesta/Diclegis</b>		BONJESTA
		DICLEGIS
		doxylamine succinate/pyridoxine hydrochloride
<b>Buprenorphine Opioid Dependence</b>		buprenorphine hcl
		buprenorphine hydrochloride
<b>Camzyos</b>		CAMZYOS
<b>Cannabidiol</b>		EPIDIOLEX
<b>Carbaglu</b>		CARBAGLU
		carglumic acid
<b>CFTR</b>		ALYFTREK
		KALYDECO
		ORKAMBI
		SYMDEKO
		TRIKAFTA
<b>CGRP</b>	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	AIMOVIG
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	AJOVY
	Preferred Products: Aimovig, Ajovy, Emgality, Nurtec, Qulipta, Ubrelvy	EMGALITY

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Aimovig, Ajoyv, Emgality, Nurtec, Qulipta, Ubrelvy	NURTEC
	Preferred Products: Aimovig, Ajoyv, Emgality, Nurtec, Qulipta, Ubrelvy	QULIPTA
	Preferred Products: Aimovig, Ajoyv, Emgality, Nurtec, Qulipta, Ubrelvy	UBRELVY
	Preferred Products: Aimovig, Ajoyv, Emgality, Nurtec, Qulipta, Ubrelvy	ZAVZPRET
<b>Cholestasis Pruritus</b>		BYLVAY
		BYLVAY (PELLETS)
		LIVMARLI
<b>Cibinqo</b>		CIBINQO
<b>Combination NSAID</b>		DUEXIS
		ibuprofen/famotidine
		naproxen/esomeprazole magnesium
		VIMOVO
<b>Constipation Agents</b>	Preferred Products: Symproic, Trulance, Movantik	AMITIZA
	Preferred Products: Symproic, Trulance, Movantik	IBSRELA
	Preferred Products: Symproic, Trulance, Movantik	LINZESS
	Preferred Products: Symproic, Trulance, Movantik	lubiprostone
	Preferred Products: Symproic, Trulance, Movantik	MOTTEGRITY
	Preferred Products: Symproic, Trulance, Movantik	MOVANTIK
	Preferred Products: Symproic, Trulance, Movantik	prucalopride
	Preferred Products: Symproic, Trulance, Movantik	RELISTOR
	Preferred Products: Symproic, Trulance, Movantik	SYMPROIC
	Preferred Products: Symproic, Trulance, Movantik	TRULANCE
<b>Corticotropin</b>		ACTHAR
		ACTHAR GEL
		CORTROPHIN
<b>Crenessity</b>		CRENESSITY
<b>Ctexli</b>		CTEXLI
<b>Daybue</b>		DAYBUE
<b>Dojolvi</b>		DOJOLVI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Dry Eye Disease		CEQUA
		cyclosporine
		EYSUVIS
		MIEBO
		RESTASIS
		RESTASIS MULTIDOSE
		TRYPTYR
		TYRVAYA
		VEVYE
	XIIDRA	
Duvyzat		DUVYZAT
Efgartigimod		VYVGART HYTRULO
Elagolix/Relugolix		MYFEMBREE
		ORIAHNN
		ORILISSA
Elmiron		ELMIRON
Empaveli		EMPAVELI
Endari		ENDARI
		l-glutamine
Enspryng		ENSPRYNG
Eohilia		EOHILIA
Fabhalta		FABHALTA
Filspari		FILSPARI
Filsuvez		FILSUVEZ
Fintepla		FINTEPLA
Furoscix		FUROSCIX
Galafold		GALAFOLD
Gattex		GATTEX
GLP-1 Agonists	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	BYDUREON BCISE
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	BYETTA
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	EXENATIDE
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	liraglutide
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	MOUNJARO
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	OZEMPIC

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	RYBELSUS
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	TRULICITY
	Preferred Products: Ozempic, Rybelsus, Trulicity, Bydureon, Mounjaro	VICTOZA
<b>Growth Hormone</b>	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	GENOTROPIN
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	GENOTROPIN MINIQUICK
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	HUMATROPE
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NGENLA
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NORDITROPIN FLEXPRO
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NUTROPIN AQ NUSPIN 10
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NUTROPIN AQ NUSPIN 20
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	NUTROPIN AQ NUSPIN 5
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	OMNITROPE
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SAIZEN
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SEROSTIM
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SKYTROFA
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	SOGROYA
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	ZOMACTON
	Preferred Product: Norditropin, Genotropin, Genotropin MiniQuick, Omnitrope	ZORBTIVE
<b>HCN Channel Blocker</b>		CORLANOR
		ivabradine hydrochloride
<b>Hemlibra</b>		HEMLIBRA
<b>Hemophilia</b>		HYMPAVZI
<b>Hemophilia Agents</b>		ADVATE
		ADYNOVATE
		AFSTYLA
		ALHEMO

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		ALPHANATE
		ALPHANINE SD
		ALPROLIX
		ALTUVIIIIO
		BENEFIX
		COAGADEX
		CORIFACT
		ELOCTATE
		ESPEROCT
		FEIBA
		HEMLIBRA
		HEMOFIL M
		HUMATE-P
		IDELVION
		IXINITY
		JIVI
		KOATE
		KOATE-DVI
		KOGENATE FS
		KOVALTRY
		NOVOEIGHT
		NOVOSEVEN RT
		NUWIQ
		OBIZUR
		PROFILNINE
		QFITLIA
		REBINYN
		RECOMBINATE
		RIXUBIS
		SEVENFACT
		TRETTEN
		VONVENDI
		WILATE
		XYNTHA
		XYNTHA SOLOFUSE
<b>Hepatitis C Direct Acting Antivirals</b>	<b>Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi</b>	EPCLUSA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	HARVONI
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	LEDIPASVIR/SOFOSBUVIR
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	MAVYRET
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	SOFOSBUVIR/VELPATASVIR
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	SOVALDI
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	VOSEVI
	Preferred Products: authorized generic sofosbuvir/velpatasvir, Epclusa, authorized generic ledipasvir/sofosbuvir, Harvoni, Mavyret, and Vosevi	ZEPATIER
<b>Hereditary Angioedema</b>		ANDEMBRY
		BERINERT
		EKTERLY
		FIRAZYR
		HAEGARDA
		icatibant acetate
		KALBITOR
		ORLADEYO
		RUCONEST
		sajazir
		TAKHZYRO
<b>Hetlioz</b>		HETLIOZ
		HETLIOZ LQ
		tasimelteon
<b>HSDD</b>		ADDYI

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		VYLEESI
<b>Hyftor</b>		HYFTOR
<b>Hyperhidrosis</b>		QBREXZA
		SOFDRA
<b>Imcivree</b>		IMCIVREE
<b>Inhaled Antibiotics</b>		BETHKIS
		CAYSTON
		KITABIS PAK
		TOBI
		TOBI PODHALER
		TOBRAMYCIN
<b>Interleukin (IL)-1 Inhibitors</b>		ARCALYST
<b>Interleukin (IL)-4 Inhibitors</b>		DUPIXENT
<b>Interleukin (IL)-5 Inhibitors</b>		FASENRA PEN
		NUCALA
<b>Interleukin-13 (IL-13) Antagonist</b>		ADBRY
		EBGLYSS
<b>Interleukin-31 Inhibitor</b>		NEMLUVIO
<b>Interstitial Lung Disease</b>		ESBRIET
		OFEV
		PIRFENIDONE
<b>Iron Chelation</b>	<b>Preferred Products: Exjade, Jadenu</b>	deferasirox
	<b>Preferred Products: Exjade, Jadenu</b>	deferiprone
	<b>Preferred Products: Exjade, Jadenu</b>	EXJADE
	<b>Preferred Products: Exjade, Jadenu</b>	FERRIPROX
	<b>Preferred Products: Exjade, Jadenu</b>	FERRIPROX TWICE-A-DAY
	<b>Preferred Products: Exjade, Jadenu</b>	JADENU
	<b>Preferred Products: Exjade, Jadenu</b>	JADENU SPRINKLE
<b>Isturisa</b>		ISTURISA
<b>Ivermectin</b>		IVERMECTIN
		STROMECTOL
<b>Joenja</b>		JOENJA
<b>Jynarque</b>		JYNARQUE
		tolvaptan
<b>Korlym</b>		KORLYM
		mifepristone

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
Long Acting Insulin	Preferred Products: Tresiba	INSULIN DEGLUDEC
	Preferred Products: Tresiba	INSULIN DEGLUDEC FLEXTOUCH
	Preferred Products: Semglee, Insulin glargine-yfgn	INSULIN GLARGINE
	Preferred Products: Semglee, Insulin glargine-yfgn	INSULIN GLARGINE SOLOSTAR
	Preferred Products: Semglee, Insulin glargine-yfgn	LANTUS
	Preferred Products: Semglee, Insulin glargine-yfgn	LANTUS SOLOSTAR
Lupus		BENLYSTA
		LUPKYNIS
Myalept		MYALEPT
Neurokinin Receptor Antagonists		VEOZAH
Neurotrophic Keratitis		OXERVATE
Niemann-Pick Disease Type C Agents		AQNEURSA
		MIPLYFFA
Northera		droxidopa
		NORTHERA
Ohtuvayre		OHTUVAYRE
Opioids ER		BELBUCA
		buprenorphine
		BUTRANS
		CONZIP
		fentanyl
		HYDROCODONE BITARTRATE ER
		hydromorphone hcl er
		hydromorphone hydrochloride er
		HYSINGLA ER
		MORPHINE SULFATE ER
		MS CONTIN
		NUCYNTA ER
		OXYCODONE HYDROCHLORIDE ER
		OXYCONTIN
		OXYMORPHONE HYDROCHLORIDE ER
		OXYMORPHONE HYDROCHLORIDEER
		TRAMADOL HCL ER

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		tramadol hydrochloride er
		XTAMPZA ER
<b>Opzelura</b>		OPZELURA
<b>Otezla</b>		OTEZLA
<b>Oxybate</b>		LUMRYZ
		LUMRYZ STARTER PACK
		SODIUM OXYBATE
		XYREM
		XYWAV
<b>Parathyroid Hormone Analog for Osteoporosis</b>	<b>Preferred Products: Tymlos, Forteo</b>	BONSITY
	<b>Preferred Products: Tymlos, Forteo</b>	FORTEO
	<b>Preferred Products: Tymlos, Forteo</b>	TERIPARATIDE
	<b>Preferred Products: Tymlos, Forteo</b>	TYMLOS
<b>PCSK-9 Inhibitors</b>	<b>Preferred Product: Repatha</b>	PRALUENT
	<b>Preferred Product: Repatha</b>	REPATHA
	<b>Preferred Product: Repatha</b>	REPATHA PUSHTRONEX SYSTEM
	<b>Preferred Product: Repatha</b>	REPATHA SURECLICK
<b>Peginterferon</b>		PEGASYS
<b>Phenylketonuria</b>		javygtor
		KUVAN
		PALYNZIQ
		sapropterin dihydrochloride
<b>Primary Biliary Cholangitis</b>		IQIRVO
		LIVDELZI
<b>Procysbi</b>		PROCYSBI
<b>Pseudobulbar Affect</b>		NUDEXTA
<b>Pulmonary Arterial Hypertension</b>		ADCIRCA
		ADEMPAS
		alyq
		ambrisentan
		bosentan
		LETAIRIS
		LIQREV
		OPSUMIT
		OPSYNVI
		ORENITRAM
		ORENITRAM TITRATION KIT MONTH 1

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		ORENITRAM TITRATION KIT MONTH 2
		ORENITRAM TITRATION KIT MONTH 3
		REVATIO
		sildenafil citrate
		tadalafil
		TADLIQ
		TRACLEER
		TYVASO
		TYVASO DPI INSTITUTIONAL KIT
		TYVASO DPI MAINTENANCE KIT
		TYVASO DPI TITRATION KIT
		TYVASO REFILL KIT
		TYVASO STARTER KIT
		UPTRAVI
		UPTRAVI TITRATION PACK
		VENTAVIS
		WINREVAIR
		YUTREPIA
<b>Pyrukynd</b>		PYRUKYND
		PYRUKYND TAPER PACK
<b>Radicava</b>		RADICAVA ORS
		RADICAVA ORS STARTER KIT
<b>Recorlev</b>		RECORLEV
<b>Relyvrio</b>		RELYVRIO
<b>Resmetirom</b>		REZDIFFRA
<b>Rezurock</b>		REZUROCK
<b>Risdiplam</b>		EVRYSDI
<b>Rivfloza</b>		RIVFLOZA
<b>SA Oncology</b>		abiraterone acetate
		abirtega
		AFINITOR
		AFINITOR DISPERZ
		AKEEGA
		ALECENSA
		ALUNBRIG
		AUGTYRO
		AVMAPKI FAKZYNJA CO-PACK
		AYVAKIT
		BALVERSA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		BESREMI
		bexarotene
	<b>Preferred Products: generic imatinib, generic dasatinib</b>	BOSULIF
		BRAFTOVI
		BRUKINSA
		CABOMETYX
		CALQUENCE
		capecitabine
		CAPRELSA
		COMETRIQ
		COPIKTRA
		COTELLIC
		DANZITEN
		dasatinib
		DAURISMO
		ENSACOVE
		ERIVEDGE
		ERLEADA
		erlotinib hydrochloride
		everolimus
		FOTIVDA
		FRUZAQLA
		GAVRETO
		gefitinib
		GILOTRIF
		GLEEVEC
		GOMEKLI
		HYCAMTIN
		IBRANCE
		IBTROZI
		ICLUSIG
		IDHIFA
		imatinib mesylate
		IMBRUVICA
		IMKELDI
		INLYTA
		INQOVI
		INREBIC
		IRESSA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		ITOVEBI
		IWILFIN
		JAKAFI
		JAYPIRCA
		KISQALI
		KISQALI FEMARA 200 DOSE
		KISQALI FEMARA 400 DOSE
		KISQALI FEMARA 600 DOSE
		KOSELUGO
		KRAZATI
		lapatinib ditosylate
		LAZCLUZE
		lenalidomide
		LENVIMA 10 MG DAILY DOSE
		LENVIMA 12MG DAILY DOSE
		LENVIMA 14 MG DAILY DOSE
		LENVIMA 18 MG DAILY DOSE
		LENVIMA 20 MG DAILY DOSE
		LENVIMA 24 MG DAILY DOSE
		LENVIMA 4 MG DAILY DOSE
		LENVIMA 8 MG DAILY DOSE
		LONSURF
		LORBRENA
		LUMAKRAS
		LYNPARZA
		LYSODREN
		LYTGOBI
		MATULANE
		MEKINIST
		MEKTOVI
		NERLYNX
		NEXAVAR
		NILOTINIB
		nilotinib hydrochloride
		NINLARO
		NUBEQA
		ODOMZO
		OGSIVEO
		OJEMDA

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		OJJAARA
		ONUREG
		ORGOVYX
		ORSERDU
		pazopanib hydrochloride
		PEMAZYRE
		PIQRAY 200MG DAILY DOSE
		PIQRAY 250MG DAILY DOSE
		PIQRAY 300MG DAILY DOSE
		POMALYST
		QINLOCK
		RETEVMO
		REVLIMID
		REVUFORJ
		REZLIDHIA
		ROMVIMZA
		ROZLYTREK
		RUBRACA
		RYDAPT
		SCEMBLIX
		sorafenib
		sorafenib tosylate
		SPRYCEL
		STIVARGA
		sunitinib malate
		SUTENT
		TABRECTA
		TAFINLAR
		TAGRISSO
		TALZENNA
		TARCEVA
		TARGETIN
	<b>Preferred Products: generic imatinib, generic dasatinib</b>	TASIGNA
		TAZVERIK
		temozolomide
		TEPMETKO
		THALOMID
		TIBSOVO
		torpenz

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		tretinoin
		TRUQAP
		TUKYSA
		TURALIO
		TYKERB
		VANFLYTA
		VENCLEXTA
		VENCLEXTA STARTING PACK
		VERZENIO
		VITRAKVI
		VIZIMPRO
		VONJO
		VORANIGO
		VOTRIENT
		WELIREG
		XALKORI
		XELODA
		XOSPATA
		XPOVIO
		XPOVIO 60 MG TWICE WEEKLY
		XPOVIO 80 MG TWICE WEEKLY
		XTANDI
		YONSA
		ZEJULA
		ZELBORAF
		ZOLINZA
		ZYDELIG
		ZYKADIA
		ZYTIGA
<b>Samsca</b>		SAMSCA
		tolvaptan
<b>Skyclarys</b>		SKYCLARYS
<b>Spevigo</b>		SPEVIGO
<b>SSIA</b>		NUPLAZID
<b>Strensiq</b>		STRENSIQ
<b>Subcutaneous Immune Globulins</b>		CUTAQUIG
		CUVITRU
		GAMMAGARD LIQUID
		GAMMAKED

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		GAMUNEX-C
		HIZENTRA
		HYQVIA
		XEMBIFY
<b>Substrate Reduction Therapy</b>		CERDELGA
		miglustat
		OPFOLDA
		yargesa
		ZAVESCA
<b>Sucraid</b>		SUCRAID
<b>Sunosi</b>		SUNOSI
<b>Tarpeyo</b>		TARPEYO
<b>Tavneos</b>		TAVNEOS
<b>Tezspire</b>		TEZSPIRE
<b>Thrombopoietin Receptor Agonists</b>		ALVAIZ
		DOPTELET
		eltrombopag olamine
		MULPLETA
		PROMACTA
		TAVALISSE
<b>Topical AK Basal Cell Carcinoma Warts Agents</b>		CARAC
		diclofenac sodium
		EFUDEX
		FLUOROURACIL
		imiquimod
		imiquimod pump
		KLISYRI
		TOLAK
		ZYCLARA
		ZYCLARA PUMP
<b>Topical Antifungals</b>		ciclodan
		ciclopirox nail lacquer
		JUBLIA
		KERYDIN
		tavaborole
<b>Topical Doxepin</b>		doxepin hydrochloride
		PRUDOXIN

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		ZONALON
<b>Topical NSAID</b>		DICLOFENAC EPOLAMINE
		FLECTOR
		LICART
<b>Topiramate ER</b>		QUDEXY XR
		topiramate er
		TROKENDI XR
<b>Transmucosal Immediate Release Fentanyl</b>		FENTANYL CITRATE
		FENTANYL CITRATE ORAL TRANSMUCOSAL
		FENTORA
<b>Tryngolza</b>		TRYNGOLZA
<b>TRYVIO</b>		TRYVIO
<b>Urea Cycle Disorders</b>		BUPHENYL
		OLPRUVA
		PHEBURANE
		RAVICTI
		sodium phenylbutyrate
<b>Vanrafia</b>		VANRAFIA
<b>Verkazia</b>		VERKAZIA
<b>Verquvo</b>		VERQUVO
<b>Vijoice</b>		VIJOICE
<b>VMAT2 Inhibitors</b>		AUSTEDO
		AUSTEDO PATIENT TITRATION KIT
		AUSTEDO XR
		AUSTEDO XR PATIENT TITRATION KIT
		INGREZZA
		tetrabenazine
		XENAZINE
<b>Vowst</b>		VOWST
<b>Voxzogo</b>		VOXZOGO
<b>Voydeya</b>		VOYDEYA
<b>Vtama</b>		VTAMA
<b>Vykat XR</b>		VYKAT XR
<b>Wakix</b>		WAKIX
<b>Weight Loss Agents</b>		ADIPEX-P
		benzphetamine hcl
		CONTRAVE
		diethylpropion hcl

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.

Utilization Management Program	Preferred Product(s)	Drug(s) in Program
		DIETHYLPROPION HCL ER
		diethylpropion hydrochloride
		DIETHYLPROPION HYDROCHLORIDE ER
		LOMAIRA
		ORLISTAT
		phendimetrazine tartrate
		PHENDIMETRAZINE TARTRATE ER
		phentermine hcl
		phentermine hydrochloride
		phentermine/topiramate er
		QSYMIA
		XENICAL
<b>Weight Management</b>		SAXENDA
		WEGOVY
		ZEPBOUND
<b>Winlevi</b>		WINLEVI
<b>Xdemvy</b>		XDEMVI
<b>Xermelo</b>		XERMELO
<b>Xhance</b>		XHANCE
<b>Xolair</b>		XOLAIR
<b>Xolremdi</b>		XOLREMDI
<b>Xphozah</b>		XPHOZAH
<b>Yorvipath</b>		YORVIPATH
<b>Zelsuvmi</b>		ZELSUVMI
<b>Zeposia</b>	<b>Preferred Products for UC: Refer to Policy</b>	ZEPOSIA
	<b>Preferred Products for UC: Refer to Policy</b>	ZEPOSIA 7-DAY STARTER PACK
<b>Zilbrysq</b>		ZILBRYSQ
<b>Zokinvy</b>		ZOKINVY
<b>Zoryve</b>		ZORYVE

This list may not be all inclusive. This list is subject to change. New-to-market products and variations of those products will not be added to the Utilization Management Program until they have been evaluated and approved by Prime Therapeutics. Please discuss with your health care provider before you switch any medications to ensure clinically appropriate use. This list is not intended to dictate to physicians how to practice medicine or intended to replace the judgment of your physician. Prime Therapeutics is not liable for any treatment administered or prescribed as a result of this Utilization Management information. Additional restrictions may apply. Neither this document, nor the successful adjudication of a pharmacy claim, is guarantee of payment. Please refer to your member guide for detailed information regarding your pharmacy benefits, including your benefit design, out-of-pocket costs, prior review and restricted access medication requests, and applicable exclusions. For more information, please contact your Prime Therapeutics representative. All brand names are the property of their respective owner". NetResults is a trademark of Prime Therapeutics LLC.